# Brainstorm Cell Therapeutics Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Brainstorm Cell Therapeutics Inc.).

## Overview

Brainstorm Cell Therapeutics Inc. is a U.S.-based biotechnology company focused on developing autologous cell therapies for neurodegenerative diseases. Its core platform, NurOwn®, uses patients’ own bone marrow-derived mesenchymal stem cells that are induced to secrete neurotrophic factors intended to modulate neuroinflammation and support neuronal survival. The company’s most advanced program is a Phase 3b trial in ALS, and it also has research efforts in progressive multiple sclerosis, Alzheimer’s disease, and exosome-based technologies. Brainstorm is still in the development stage and has not generated operating revenue, so its business is centered on clinical development, regulatory progress, manufacturing readiness, and intellectual property protection.

## Products & services

• NurOwn® autologous cell therapy platform
• Phase 3b ALS clinical development program
• Progressive multiple sclerosis cell therapy research
• Exosome-based therapeutic technology
• GMP manufacturing and clinical supply of NurOwn®
• Intellectual property licensing and patent portfolio

- **Autologous cell therapy platform** (70%) — Patient-derived MSC-NTF cell therapy designed to treat neurodegenerative disease.
- **Clinical development programs** (20%) — Late-stage clinical trials and regulatory work for ALS and other indications.
- **Exosome-based therapeutics** (5%) — Preclinical and patent-protected exosome technologies derived from the core platform.
- **Manufacturing and supply capabilities** (5%) — Centralized GMP production and distribution of NurOwn® for trials and potential commercialization.

- NurOwn® autologous cell therapy platform
- Phase 3b ALS clinical development program
- Progressive multiple sclerosis cell therapy research
- Exosome-based therapeutic technology
- GMP manufacturing and clinical supply of NurOwn®
- Intellectual property licensing and patent portfolio

## Customers

Brainstorm does not sell a commercial product today; its current 'customers' are primarily clinical trial participants, investigators, and regulatory stakeholders supporting development of NurOwn®. If approved, the therapy would be used by patients with ALS and potentially other neurodegenerative diseases such as progressive multiple sclerosis and Alzheimer’s disease. In the near term, the company’s value proposition is directed toward physicians, trial sites, and future healthcare systems that would adopt a specialized autologous therapy requiring controlled manufacturing and administration. The company also depends on licensing and collaboration counterparties, including the technology transfer owner of the NurOwn® rights, for commercialization rights and development continuity.

- **ALS clinical trial participants** (primary) — Patients with ALS enrolled in Phase 3b studies who receive NurOwn® to evaluate safety and efficacy.
- **Clinical investigators and trial sites** (primary) — Hospitals and research centers in the U.S. that run the late-stage trials and administer the therapy.
- **Regulatory agencies** (primary) — FDA and other regulators that review trial design, CMC controls, and potential approval pathways.
- **Future commercial neurology providers** (secondary) — Specialty physicians and treatment centers that would use NurOwn® if it reaches market approval.
- **Potential partners and licensors** (secondary) — Organizations that may fund, license, or co-develop the platform and exosome technologies.

- ALS patients enrolled in late-stage clinical trials
- Clinical investigators and trial sites administering NurOwn®
- Regulators evaluating safety, efficacy, and manufacturing controls
- Future neurologists and specialty centers if the therapy is approved
- Potential licensing or collaboration partners for development and commercialization
- Healthcare systems that would reimburse a niche neurodegenerative therapy

## Geography

Brainstorm is incorporated in Delaware and has its principal executive offices in New York, with additional operations in Israel and Massachusetts. Its R&D center is in Petach Tikva, Israel, and it leases a GMP manufacturing center in Tel Aviv to produce NurOwn® for clinical use and potential shipment into the EU and Israel. The company stated that all of its late-stage ALS and PMS clinical trial sites are in the United States, making the U.S. the center of its clinical development activity. Its patent portfolio spans the United States, Europe, Israel, Australia, and other global markets, which is important because the company’s value depends heavily on cross-border IP protection and future commercialization rights.

- Headquartered in New York, United States
- R&D center in Petach Tikva, Israel
- GMP manufacturing center in Tel Aviv, Israel
- Late-stage ALS and PMS trial sites are all in the United States
- Patent coverage across the U.S., Europe, Israel, Australia, and other markets
- Manufacturing footprint supports potential EU and Israeli supply

## Strategy

Brainstorm’s strategy is to advance NurOwn® through late-stage clinical development and regulatory engagement, with the Phase 3b ALS program as the key value driver. The company is also working to improve manufacturing efficiency, product stability, and scale-up capacity so the therapy can be produced centrally and distributed to trial sites or future commercial locations. A second strategic pillar is expanding its intellectual property estate, including exosome-based technologies, to protect future therapeutic applications and extend the platform beyond ALS. Because the company has no operating revenue, execution depends on funding, trial progress, regulatory outcomes, and the ability to preserve manufacturing and IP advantages.

- **Complete and de-risk the Phase 3b ALS program** (short-term) — Clinical success is the main path to value creation and future commercialization.
- **Strengthen manufacturing and CMC readiness** (short-term) — Cell therapies require reliable, scalable, and stable production to support trials and eventual launch.
- **Expand and defend intellectual property** (medium-term) — Patent protection is essential for exclusivity in a platform-based biotech business.
- **Broaden the platform into additional neurodegenerative and exosome applications** (long-term) — A broader pipeline can reduce dependence on a single indication and increase long-term optionality.

- Advance NurOwn® through Phase 3b ALS development
- Maintain FDA and other regulatory alignment on trial design and CMC
- Improve manufacturing efficiency, stability, and shelf life
- Scale centralized production for trial supply and future commercialization
- Expand exosome-based research beyond the core ALS program
- Protect the platform with patents across major global markets

## Risks

Brainstorm faces the classic risks of a development-stage biotech company: clinical failure, regulatory delays, and uncertainty around whether its cell therapy will demonstrate sufficient efficacy and safety for approval. The company also depends on continued access to capital, and its recent delisting from Nasdaq to OTCQB highlights financing and liquidity pressure that can limit investor access and raise the cost of capital. Manufacturing risk is material because autologous cell therapies require tightly controlled CMC processes, and any failure in production consistency, shelf life, or distribution could disrupt trials or future commercialization. In addition, the company’s reliance on intellectual property, third-party licensing rights, and a small workforce concentrated in the U.S. and Israel creates operational and geopolitical exposure, while broader biotech sector risks include reimbursement uncertainty, competition from alternative ALS approaches, and adverse market conditions that can affect funding availability.

- **Clinical development failure** [critical] — NurOwn® is still in late-stage testing, so efficacy or safety shortfalls could prevent approval and commercialization.
- **Capital and liquidity constraints** [high] — The company has no operating revenue and has relied on short-term borrowing and equity markets to fund operations.
- **Regulatory and CMC execution risk** [high] — Cell therapy approval depends on manufacturing controls, comparability, and FDA alignment on trial design.
- **Nasdaq delisting and market access** [high] — OTCQB trading can reduce liquidity, investor demand, and the company’s ability to raise capital efficiently.
- **Intellectual property dependence** [medium] — Commercial rights depend on patents and a licensing agreement with Ramot for NurOwn® technology.
- **Internal control weakness** [medium] — A reported material weakness in internal controls increases the risk of financial reporting errors.

- Clinical trial failure or inconclusive efficacy data could eliminate the main value driver
- Regulatory delays or unfavorable FDA feedback could slow or block approval
- Funding risk is high because the company has no operating revenue and depends on external capital
- Manufacturing and CMC execution risk is material for an autologous cell therapy
- Delisting and OTCQB trading can reduce liquidity and increase financing friction
- IP disputes or loss of licensed rights could weaken commercialization prospects
- Geopolitical and cross-border operating risk exists because key functions are split between the U.S. and Israel

## Accounting

Brainstorm’s financial statements are dominated by development-stage biotech accounting, where expenses are driven by R&D, clinical operations, and stock-based compensation rather than revenue recognition. The company reported no operating revenue, so investors should focus on how clinical and manufacturing spending is classified and whether costs are capitalized or expensed under U.S. GAAP. Share-based compensation is a key judgment area because the Black-Scholes inputs, expected forfeitures, and vesting assumptions can materially affect reported net loss. The company also disclosed a material weakness in internal controls, which raises the risk of misstatement and makes period-to-period comparisons less reliable. Because the business depends on external financing and short-term debt, liquidity disclosures, going-concern considerations, and debt classification are also important for analysis.

- **Stock-based compensation valuation** — Affects operating loss and earnings per share
- **R&D expense recognition** — Affects comparability of operating results
- **Internal control weakness** — Affects reliability of reported numbers
- **Liquidity and debt classification** — Affects solvency and financing assessment

- No operating revenue means reported results are driven by R&D and G&A expense timing
- Stock-based compensation depends on subjective valuation inputs and can materially affect net loss
- Clinical trial and manufacturing costs are expensed as incurred, affecting quarterly volatility
- Material weakness in internal controls increases reporting risk
- Short-term debt and financing costs affect liquidity and balance sheet presentation
- Going-concern and funding disclosures are important for a pre-revenue biotech

---

*Last updated: 2026-08-11T04:46:23.001951+00:00*